While the connection of PYGM/PYGL to RTT remains to be established, the beneficial effects of glycogen synthase kinase 3 (GSK3) inhibition in RTT models suggest that PYGM/PYGL modulation may offer therapeutic potential (Llavero and Zugaza 2024). The gene discussed is PYGL; the disease is Rett syndrome.